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OBJECTIVE — Interleukin-1receptorantagonist(IL-1Ra),anaturalinhibitorofinterleukin-
1, has been shown to improve -cell function and glycemic control in patients with type 2
diabetes. The aim of this study was to investigate whether baseline systemic levels of IL-1Ra are
associated with incident type 2 diabetes during more than 10 years of follow-up.
RESEARCH DESIGN AND METHODS — We measured serum IL-1Ra concentrations
in a nested case-control study (181 case and 376 age-, sex-, and BMI-matched normoglycemic
control subjects) within the Whitehall II cohort (U.K.).
RESULTS — IL-1Ra concentrations were higher in case subjects (P  0.0006) and associated
withincidenttype2diabetes(oddsratiofora1-SDincreaseofIL-1Ra1.48[95%CI1.21–1.80]).
This association remained signiﬁcant after adjustment for multiple potential confounders but
was attenuated by adjusting for 2-h glucose.
CONCLUSIONS — Our ﬁndings indicate that individuals who will develop type 2 diabetes
are characterized by a complex immune activation that also includes upregulation of the anti-
inﬂammatory cytokine IL-1Ra.
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S
ystemic concentrations of several
acute-phase proteins, cytokines,
and chemokines are elevated in in-
dividuals who will subsequently develop
type 2 diabetes compared with those in
individuals who remain disease free (1–
3). Immune mediators such as interleu-
kin-6 and monocyte chemoattractant
protein-1 have been shown to interfere
with insulin signaling in fat, liver, and
muscle cells (1,4), whereas, in particular,
the proinﬂammatory cytokine interleu-
kin-1 inhibits -cell function and pro-
motes -cell apoptosis (5). Therefore,
low-grade inﬂammation may contribute
to diabetes development both by induc-
ing insulin resistance and reducing insu-
lin secretion.
The importance of interleukin-1
andinterleukin-1receptorantagonist(IL-
1Ra) was emphasized by a randomized,
double-blind, clinical trial; IL-1Ra im-
proved -cell function and glycemic con-
trol in patients with type 2 diabetes (6). It
is thus tempting to speculate that high
circulating IL-1Ra concentrations could
indicate decreased risk of type 2 diabetes
much like increased adiponectin levels
are associated with lower incidence of
type2diabetes(7).SystemicIL-1Ralevels
are increased in patients with obesity, im-
paired glucose tolerance, and the meta-
bolic syndrome in cross-sectional studies
(8–10). Longitudinal data on the rela-
tionship between IL-1Ra and the risk of
type 2 diabetes are not available. There-
fore, the aim of the current study was to
investigate whether systemic levels of IL-
1Ra are associated with incident type 2
diabetes in a nested case-control study
within the prospective Whitehall II co-
hort study.
RESEARCH DESIGN AND
METHODS— We present results
from a nested case-control study within
the Whitehall II cohort, which was estab-
lished in 1985 and included 10,308 civil
servants age 35–55 years (11). Phase 3
(1991–1994) of the study was the ﬁrst
phase where glucose tolerance was as-
sessed by a 75-g oral glucose tolerance
test and is the baseline for the current
study (n  7,537). Participants were fol-
lowed through postal questionnaires at
2.5-year intervals (phases 4–8) and fur-
ther clinical examinations (including an
oral glucose tolerance test) in 1997–1999
(phase 5) and 2003–2004 (phase 7) (12).
Individuals without type 2 diabetes at
baselineandwithincidenttype2diabetes
duringthefollow-upperiodof11.53.0
years served as case subjects (n  181).
The control subjects (n  376), with nor-
malglucosetoleranceatbaselineanddur-
ing the follow-up, were frequency
matched to case subjects for age (5-year
bands), sex, and BMI (5 kg/m
2 bands).
Furtherdetailsontheselectioncriteriafor
this nested case-control study and infor-
mation on the collection of anthropomet-
ric, metabolic, socioeconomic, and
immunologicalvariablesandonstatistical
analysis are given in an online appendix
(available at http://dx.doi.org/10.2337/
dc08-1161).
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and control subjects are shown in Table
A1 of the online appendix. The compari-
sonoftheincludedandexcludeddiabetic
case subjects revealed only a few signiﬁ-
cant differences: selected case subjects
were less likely to be women and smok-
ers, were more likely to be ex-smokers,
and had a marginally lower BMI. Other
comparisons between the two groups
were not signiﬁcant (data not shown).
Characteristics of control subjects in our
selection mainly reﬂected the selection
criteria (normal glucose tolerance
throughout the study and matching for
age, sex, and BMI to case subjects): they
were slightly older and had a higher BMI,
waist circumference, and diastolic blood
pressure but lower fasting and 2-h glu-
cose compared with the rest of the cohort
who were nondiabetic at baseline and fol-
low-up (data not shown).
IL-1Ra concentrations at baseline
were higher in case subjects (median
232.8 pg/ml [25th–75th percentiles
180.7–342.2]) than in control subjects
(207.6 pg/ml [159.3–274.8]) (P 
0.0006). A 1-SD increase of IL-1Ra
(157.7 pg/ml) was associated with inci-
dent type 2 diabetes in models that ad-
justedformultiplepotentialconfounders,
including age, sex, waist circumference,
cardiovascular risk factors, socioeco-
nomic status, proinﬂammatory media-
tors, and fasting glycemia (Table 1).
Further inclusion of BMI had virtually no
impact on odds ratio (model 2 plus BMI
odds ratio 1.41 [95% CI 1.13–1.77]; P 
0.0027). However, addition of 2-h glu-
cose led to reduced effect sizes and loss of
statistical signiﬁcance (Table 1).
CONCLUSIONS— Elevatedlevelsof
IL-1Ra were associated with an increased
risk of developing type 2 diabetes in this
nested case-control study. We found a
slightattenuationofthisassociationwhen
adjusting for waist circumference, which
is consistent with IL-1Ra production in
adipose tissue (13). It is remarkable that
the association was stable to adjustment
for a range of further potential confound-
ers, including fasting glucose and insulin.
However, adjustment for 2-h glucose at-
tenuated the association. This ﬁnding
could be interpreted to indicate that in-
creased IL-1Ra levels are a reaction to and
not a cause of early postprandial hyper-
glycemia before the onset of diabetes.
Studies with measurements of glycemic
markers and IL-1Ra at multiple time
points and analysis of their trajectories
will be needed to clarify this point.
Our ﬁndings expand observations
from cross-sectional studies that reported
elevatedlevelsofIL-1Rainthecirculation
ofindividualswithobesityandinsulinre-
sistance (8–10). Thus, individuals who
willdeveloptype2diabetesarecharacter-
izednotonlybyanupregulationofproin-
ﬂammatory immune mediators (1–3) but
also by the upregulation of at least one
anti-inﬂammatory immune marker. Be-
cause animal studies and a recent clinical
trial indicated that administration of IL-
1Ra attenuates subclinical inﬂammation,
supports -cell function/insulin secre-
tion, and may also improve insulin sensi-
tivity (6,14), it is tempting to speculate
that elevated IL-1Ra levels in individuals
at risk of type 2 diabetes may be an at-
tempt to counteract the proinﬂammatory
effects of interleukin-1 and to preserve
insulin secretion and insulin sensitiv-
ity—an effort that eventually fails. How-
ever, our data cannot rule out the
alternative interpretation that IL-1Ra has
additional metabolic effects beyond the
inhibition of interleukin-1that could lead
to insulin resistance and type 2 diabetes.
As a potential limitation of the study,
it should be mentioned that point esti-
mates and CIs are derived from non-
weighted data from a nested case-control
studyand,therefore,theirstatisticalinfer-
ence may be restricted and may not rep-
resent the best available estimate within
the context of the original cohort. Thus,
further studies will be needed to support
our hypothesis that individuals with high
risk of type 2 diabetes are characterized
bythepresenceofanearlycompensatory,
anti-inﬂammatoryresponsethatprecedes
the development of the disease. This hy-
pothesis could be tested by the analysis of
further, mainly anti-inﬂammatory im-
mune mediators, such as interleukin-10
or transforming growth factor- in addi-
tional cohorts.
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